Markets.News

RLYB  RALLYBIO CORP

+ add to watchlist

$8.12

rallybio is a privately-held early-stage biotechnology company incorporated in january 2018. our ambition is to create a world-leading biotechnology organization that transforms the lives of patients with devastating disease, built around people with an outstanding track record in pharmaceutical research and development. we will work on highly-promising drug candidates that have strong biological rationales and that can be addressed using the well-validated therapeutic modalities of small molecules, engineered proteins, and antibodies. rallybio’s founders are seasoned leaders from the biopharma industry with a wide breadth of research, development, and financial experience. the company is based in farmington, ct, at the university of connecticut’s technology incubation program. we are assembling a small team of people with an outstanding track record in pharmaceutical research and development to search for and evaluate assets using a series of robust clinical and commercial filters tha

Mkt Cap: $44.59M

52 Week High: $11.49

P/E: 0.00

52 Week Low: $1.76

Dividend: $0.00

Shares Outstanding: 5.29M

This news is delayed by 15 minutes, sign up now to get live news & full features.